- 353 Downloads
This chapter will review common noninfectious and infectious comorbidities that place patients at risk of polypharmacy and associated pharmacokinetic and pharmacodynamic drug interactions with antiretroviral agents.
KeywordsMental Health Disorder Immune Reconstitution Inflammatory Syndrome Drug Interaction Potential Subsequent Chapter Receive Protease Inhibitor
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 2.World Health Organization (WHO). Chapter 8: Clinical guidance across the continuum of care: managing common coinfections and comorbidities. In: Consolidated ARV guidelines. 2013. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/coinfection/en/. Accessed 18 June 2016
- 5.World Health Organization (WHO) (2010) Treatment of tuberculosis guidelines, 4th ed. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/. Accessed 18 June 2016
- 7.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 2016. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 15 June 2016
- 8.Centers for Disease Control and Prevention (CDC). Recommendations for the use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR. Morbidity and mortality weekly reports 2011;60:1650–1653. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm. Accessed 19 June 2016
- 9.World Health Organization (WHO) (2015) Guidelines for the treatment of malaria, 3rd ed. Available from: http://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed 18 June 2016
© Springer Science+Business Media Singapore 2016